Novartis To Acquire Gene Therapy Specialist Avexis For 8 7bn The New

Novartis To Acquire Avexis Rett Syndrome Research Trust Swiss drugmaker novartis is moving further into gene therapy by buying avexis for $8.7 billion, adding a rare disease treatment that could reap billions in sales. On april 9, swiss pharmaceutical giant novartis announced it had entered into an agreement to buy american gene therapy company avexis for $8.7bn. the acquisition comes as novartis looks to become a leader in gene therapy treatments for chronic illnesses.

Exhibit A 5 B Novartis ag agreed to acquire avexis inc. for $8.7 billion to gain a promising drug to treat a rare disease that afflicts infants, hastening a shift toward gene therapy and precision medicines. Basel, april 9, 2018 novartis announced today that it has entered into an agreement and plan of merger with avexis, inc. to acquire the us based nasdaq listed clinical stage gene therapy company for usd 218 per share or a total of usd 8.7 billion in cash. Novartis has struck an $8.7 billion deal to buy avexis. the move sees newly minted novartis ceo vas narasimhan, m.d., pay a hefty premium to establish the company as a frontrunner in. Novartis’ push into advanced therapy medical products (atmps) gathered pace this morning after it announced an $8.7bn agreement to take over gene therapy company avexis.

Novartis Embeds Avexis Into Rebrand Bioprocess Insider Novartis has struck an $8.7 billion deal to buy avexis. the move sees newly minted novartis ceo vas narasimhan, m.d., pay a hefty premium to establish the company as a frontrunner in. Novartis’ push into advanced therapy medical products (atmps) gathered pace this morning after it announced an $8.7bn agreement to take over gene therapy company avexis. Basel, april 9, 2018 novartis announced today that it has entered into an agreement and plan of merger with avexis, inc. to acquire the us based nasdaq listed clinical stage gene therapy company for usd 218 per share or a total of usd 8.7 billion in cash. Novartis gene therapies, until 2020 known as avexis, is a biotechnology company that develops treatments for rare neurological genetic disorders. Novartis ag said april 9 it will buy the gene therapy focused biotech avexis inc. for $8.7 billion, greatly expanding the swiss pharma’s bet on the promise of treating disease by altering a patient’s genetic make up. Novartis said on monday it plans to buy gene therapy company avexis in a cash deal totaling $8.7 billion. the deal is expected to be completed in mid 2018.

Avexis Renamed Novartis Gene Therapies Basel, april 9, 2018 novartis announced today that it has entered into an agreement and plan of merger with avexis, inc. to acquire the us based nasdaq listed clinical stage gene therapy company for usd 218 per share or a total of usd 8.7 billion in cash. Novartis gene therapies, until 2020 known as avexis, is a biotechnology company that develops treatments for rare neurological genetic disorders. Novartis ag said april 9 it will buy the gene therapy focused biotech avexis inc. for $8.7 billion, greatly expanding the swiss pharma’s bet on the promise of treating disease by altering a patient’s genetic make up. Novartis said on monday it plans to buy gene therapy company avexis in a cash deal totaling $8.7 billion. the deal is expected to be completed in mid 2018.

Novartis To Buy Avexis In 6 2bn Gene Therapy Deal Novartis ag said april 9 it will buy the gene therapy focused biotech avexis inc. for $8.7 billion, greatly expanding the swiss pharma’s bet on the promise of treating disease by altering a patient’s genetic make up. Novartis said on monday it plans to buy gene therapy company avexis in a cash deal totaling $8.7 billion. the deal is expected to be completed in mid 2018.